CHEK2 C1100del mutation associated with papillary renal cell carcinoma type II

CHEK2 mutations have been noted in bone, brain, breast, colon, lung, thyroid, and prostate cancer. Although now reported in both clear cell and non-clear cell renal cancer, we have not found CHEK2 2 mutations reported in the papillary type II subtype (PRCC). Here, we report a 63-year-old female with...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopez, Santiago J., Williams, H. James, Hogan, Thomas Francis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504490/
https://www.ncbi.nlm.nih.gov/pubmed/37719181
http://dx.doi.org/10.1016/j.eucr.2023.102421
_version_ 1785106735195750400
author Lopez, Santiago J.
Williams, H. James
Hogan, Thomas Francis
author_facet Lopez, Santiago J.
Williams, H. James
Hogan, Thomas Francis
author_sort Lopez, Santiago J.
collection PubMed
description CHEK2 mutations have been noted in bone, brain, breast, colon, lung, thyroid, and prostate cancer. Although now reported in both clear cell and non-clear cell renal cancer, we have not found CHEK2 2 mutations reported in the papillary type II subtype (PRCC). Here, we report a 63-year-old female with a PRCC type II with a concomitant CHEK2 C1100del mutation, who is currently in complete remission three years post tumor resection.
format Online
Article
Text
id pubmed-10504490
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-105044902023-09-17 CHEK2 C1100del mutation associated with papillary renal cell carcinoma type II Lopez, Santiago J. Williams, H. James Hogan, Thomas Francis Urol Case Rep Oncology CHEK2 mutations have been noted in bone, brain, breast, colon, lung, thyroid, and prostate cancer. Although now reported in both clear cell and non-clear cell renal cancer, we have not found CHEK2 2 mutations reported in the papillary type II subtype (PRCC). Here, we report a 63-year-old female with a PRCC type II with a concomitant CHEK2 C1100del mutation, who is currently in complete remission three years post tumor resection. Elsevier 2023-05-12 /pmc/articles/PMC10504490/ /pubmed/37719181 http://dx.doi.org/10.1016/j.eucr.2023.102421 Text en © 2023 Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Oncology
Lopez, Santiago J.
Williams, H. James
Hogan, Thomas Francis
CHEK2 C1100del mutation associated with papillary renal cell carcinoma type II
title CHEK2 C1100del mutation associated with papillary renal cell carcinoma type II
title_full CHEK2 C1100del mutation associated with papillary renal cell carcinoma type II
title_fullStr CHEK2 C1100del mutation associated with papillary renal cell carcinoma type II
title_full_unstemmed CHEK2 C1100del mutation associated with papillary renal cell carcinoma type II
title_short CHEK2 C1100del mutation associated with papillary renal cell carcinoma type II
title_sort chek2 c1100del mutation associated with papillary renal cell carcinoma type ii
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504490/
https://www.ncbi.nlm.nih.gov/pubmed/37719181
http://dx.doi.org/10.1016/j.eucr.2023.102421
work_keys_str_mv AT lopezsantiagoj chek2c1100delmutationassociatedwithpapillaryrenalcellcarcinomatypeii
AT williamshjames chek2c1100delmutationassociatedwithpapillaryrenalcellcarcinomatypeii
AT hoganthomasfrancis chek2c1100delmutationassociatedwithpapillaryrenalcellcarcinomatypeii

Ejemplares similares